Global University Venturing

Noria Therapeutics and PSMA Therapeutics have both been acquired by Bayer, which will integrate their respective assets into its own oncology portfolio.

IP Group sold a $5m stake to incoming shareholder Celltrion as part of a series A round for Iksuda, a spinout of Bath originally called Glythera.

The low Earth orbit mapping technology provider has raised more than $100m altogether, having picked up series A financing from Weru Investment in 2018.

Stablix Therapeutics has launched with $63m in equity financing to commercialise research pioneered in Henry Colecraft’s laboratory at Columbia University.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The UVC Partners-backed bus and train service hiked its valuation to $3bn in a series G debt and equity round that will fund the expansion of its routes.

Stanford has contributed to a $26m series A for Jeeves, which was announced concurrently with a $5m seed round and $100m in debt financing.

Hokkaido spinout AWL has collected fresh funding from a consortium led by Rakuten Capital.

The oncology therapy developer has filed for an IPO just two years after emerging from stealth to advance Harvard and Stanford research.

Centessa, formed earlier this year through a ten-way merger involving multiple spinouts, has completed a listing in the US.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.